01:31 , Sep 2, 2017 |  BioCentury  |  Strategy

Breach of contract

Merck & Co. Inc. Chairman and CEO Kenneth Frazier’s resignation in August from a White House advisory council was an act of principle, and a reminder that 30 years ago Merck was one of the...
23:08 , Jun 19, 2017 |  BC Extra  |  Politics & Policy

SCOTUS sides with BMS in jurisdictional case

In an 8-1 decision Monday, the U.S. Supreme Court ruled that out-of-state residents could not enter a case brought against Bristol-Myers Squibb Co. (NYSE:BMY) in California, reversing an earlier state court's decision that BMS's "extensive...
17:15 , Jun 2, 2017 |  BC Week In Review  |  Company News

AZ and Harvard Pilgrim sign two outcomes-based drug pricing contracts

Regional insurer Harvard Pilgrim Health Care Inc. (Boston, Mass.) signed two outcomes-based drug pricing contracts with AstraZeneca plc (LSE:AZN; NYSE:AZN). The insurer signed a three-year contract for AZ’s Brilinta ticagrelor, which is marketed in the U.S....
18:31 , Mar 31, 2017 |  BC Week In Review  |  Clinical News

Xarelto: Ph II GEMINI-ACS-1 data

The double-blind, international Phase II GEMINI-ACS-1 trial in 3,037 patients with ACS showed that twice-daily 2.5 mg oral Xarelto plus clopidogrel or Brilinta ticagrelor led to no significant difference in the rate of TIMI clinically...
19:55 , Mar 14, 2017 |  BC Week In Review  |  Clinical News

Savaysa: Ph IIIb ENTRUST-AF PCI started

Daiichi began the open-label, international Phase IIIb ENTRUST-AF PCI trial to evaluate 30 and 60 mg oral Savaysa once daily vs. a vitamin K antagonist for 12 months in 1,500 patients. Patients will also receive...
16:16 , Nov 30, 2016 |  BC Week In Review  |  Clinical News

Pradaxa: Completed Ph III enrollment

Boehringer completed enrollment of 2,727 patients in the open-label, international Phase III RE-DUAL PCI trial comparing 110 and 150 mg oral Pradaxa twice daily plus clopidogrel or Brilinta ticagrelor vs. triple antithrombotic therapy comprising warfarin,...
21:21 , Nov 18, 2016 |  BC Week In Review  |  Clinical News

Xarelto: Ph IIIb PIONEER AF-PCI data

The open-label, international Phase IIIb PIONEER AF-PCI trial in 2,124 patients with non-valvular AF who received background antiplatelet therapy following PCI with stenting showed that once-daily15 mg oral Xarelto plus single antiplatelet therapy (clopidogrel or...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Clinical News

Brilinta: Phase IIIb data

Top-line data from the double-blind, international Phase IIIb EUCLID trial in 13,885 symptomatic patients with PAD showed that twice-daily 90 mg oral Brilinta missed the primary endpoint of improving the time to first occurrence of...
07:00 , Oct 4, 2016 |  BC Extra  |  Clinical News

Brilinta not significantly better than clopidogrel in PAD

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Brilinta ticagrelor missed the primary endpoint in the global Phase III EUCLID trial. The anticoagulant failed to significantly reduce major cardiovascular events in patients with peripheral arterial disease compared with...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

Zontivity vorapaxar regulatory update

EMA’s CHMP recommended expanding the label of Zontivity vorapaxar from Merck to include reduction of atherothrombotic events in adults with symptomatic peripheral arterial disease (PAD). The protease-activated receptor 1 (PAR1) antagonist that inhibits thrombin-induced...